AU2015258285B2 - Predicting coronary artery disease and risk of cardiovascular events - Google Patents
Predicting coronary artery disease and risk of cardiovascular events Download PDFInfo
- Publication number
- AU2015258285B2 AU2015258285B2 AU2015258285A AU2015258285A AU2015258285B2 AU 2015258285 B2 AU2015258285 B2 AU 2015258285B2 AU 2015258285 A AU2015258285 A AU 2015258285A AU 2015258285 A AU2015258285 A AU 2015258285A AU 2015258285 B2 AU2015258285 B2 AU 2015258285B2
- Authority
- AU
- Australia
- Prior art keywords
- subject
- metabolite
- risk
- metabolites
- cad
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 145
- 230000007211 cardiovascular event Effects 0.000 title claims abstract description 44
- 239000002207 metabolite Substances 0.000 claims abstract description 228
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 47
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 238000004949 mass spectrometry Methods 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 38
- 235000021588 free fatty acids Nutrition 0.000 abstract description 24
- 150000002576 ketones Chemical class 0.000 abstract description 17
- 238000011161 development Methods 0.000 abstract description 6
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 abstract description 4
- 238000004458 analytical method Methods 0.000 description 43
- 229940024606 amino acid Drugs 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 37
- 230000010076 replication Effects 0.000 description 32
- 206010012601 diabetes mellitus Diseases 0.000 description 28
- 208000010125 myocardial infarction Diseases 0.000 description 20
- 208000032928 Dyslipidaemia Diseases 0.000 description 19
- 206010020772 Hypertension Diseases 0.000 description 19
- 208000017170 Lipid metabolism disease Diseases 0.000 description 19
- 230000000391 smoking effect Effects 0.000 description 19
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 18
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 102000015779 HDL Lipoproteins Human genes 0.000 description 11
- 108010010234 HDL Lipoproteins Proteins 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 11
- 229930195712 glutamate Natural products 0.000 description 11
- 229940049906 glutamate Drugs 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 108010076282 Factor IX Proteins 0.000 description 10
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 10
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 10
- 235000013477 citrulline Nutrition 0.000 description 10
- 229960002173 citrulline Drugs 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 238000002705 metabolomic analysis Methods 0.000 description 10
- 230000001431 metabolomic effect Effects 0.000 description 10
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 9
- 102000007330 LDL Lipoproteins Human genes 0.000 description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 description 9
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 9
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 229960003104 ornithine Drugs 0.000 description 9
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 8
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 8
- 108010074051 C-Reactive Protein Proteins 0.000 description 8
- 102100032752 C-reactive protein Human genes 0.000 description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 229960000310 isoleucine Drugs 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 150000005693 branched-chain amino acids Chemical class 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 238000002483 medication Methods 0.000 description 7
- 230000003234 polygenic effect Effects 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- 108010054218 Factor VIII Proteins 0.000 description 6
- 102000001690 Factor VIII Human genes 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 229960001230 asparagine Drugs 0.000 description 6
- 235000009582 asparagine Nutrition 0.000 description 6
- 229940009098 aspartate Drugs 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000004474 valine Substances 0.000 description 6
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 229960003121 arginine Drugs 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000012417 linear regression Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000013146 percutaneous coronary intervention Methods 0.000 description 5
- 230000002028 premature Effects 0.000 description 5
- 229960002429 proline Drugs 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000004129 fatty acid metabolism Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000004898 mitochondrial function Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- SECPZKHBENQXJG-FPLPWBNLSA-N (Z)-Palmitoleic acid Natural products CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UFAHZIUFPNSHSL-UHFFFAOYSA-N O-propanoylcarnitine Chemical compound CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000002889 oleic acids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000858 peroxisomal effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000004143 urea cycle Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940029980 drug used in diabetes Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- -1 ketone β-hydroxybutyrate Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000013180 random effects model Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Methods of assessing the risk of cardiovascular disease in a subject by detecting the level of at least one metabolite in a sample from the subject are disclosed herein. The level of the metabolite is indicative of the risk of cardiovascular disease in the subject. The metabolites may be acylcarnitines, amino acids, ketones, free fatty acids or hydroxybutyrate. The cardiovascular disease may be risk of a cardiovascular event, presence of coronary artery disease or risk of development of coronary artery disease. 7142005 1 (GHMatters) P88180.AU.1
Description
PREDICTING CORONARY ARTERY DISEASE AND RISK OF CARDIOVASCULAR EVENTS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional application of Australian Patent Application No. 2010224175 which, in turn, claims priority from U.S. Provisional Patent Application No. 61/159,077 filed 10 March 2009. The specification for each of AU2010224175 and US61/159,077 are incorporated herein by reference in their entirety.
BACKGROUND OF THE INVENTION
Coronary artery disease (CAD) is the leading cause of death in industrialized countries, and in concert with the epidemic of obesity and diabetes, is rapidly becoming the leading cause of death in developing countries. The genetic predilection of CAD is well-established; family history has been shown to be an independent risk factor for CAD, especially in early onset forms. Despite this, the genetic architecture of CAD remains largely unknown.
Many accepted risk factors for CAD are metabolic. However, there remains an incomplete mechanistic understanding of CAD risk, and equally important, a need to refine our ability to identify individuals at highest risk of cardiovascular events. Given the complex nature of CAD, evaluation with more comprehensive tools may improve risk stratification and enhance our understanding of the disease process.
SUMMARY OF THE INVENTION
In one aspect, methods for assessing risk of inherited cardiovascular disease in a subject are provided. The risk assessment may include predicting the likelihood a subsequent cardiovascular event such as a myocardial infarction, predicting development of CAD, or discriminating the presence of CAD in a subject. The methods include detecting each metabolite in a sample from the subject. The metabolite may be an acylcarnitine, an amino acid, a ketone, a free fatty acid or β-hydroxybutyrate. The levels of metabolites are then compared to a standard or to control subjects and can be used to determine the level of risk of a cardiovascular event, the risk of development of CAD or the presence of CAD in the subject.
In some embodiments, there is provided a method for assessing risk of inherited cardiovascular disease in a subject comprising: (a) detecting in a sample from the subject the level of each metabolite in a group of metabolites consisting of C5-DC, C6-DC, C8:l-OH/C6:l-DC, and C8:1-DC; (b) comparing the level of each metabolite in the sample to a non-cardiovascular disease standard; and (c) determining that the subject has an increased risk of inherited cardiovascular disease when the level of the at least one metabolite is different from the standard.
In some embodiments, there is provided a method for assessing risk of inherited cardiovascular disease in a subject comprising: (a) detecting in a sample from the subject the level of each metabolite in a group of metabolites consisting of C5-DC, C6-DC, C8:l-OH/C6:l-DC, and C8:1-DC; (b) calculating a weighted level of each metabolite by multiplying the detected level by a loading factor specific for each metabolite; (c) adding the weighted level of each metabolite in the group together to yield a factor score; (d) comparing the factor score of the sample to a non-cardiovascular disease standard; and (e) determining that the subject has an increased risk of inherited cardiovascular disease when the factor score in the subject is different from the standard
In another aspect, methods of developing a treatment plan for a subject with or at risk of developing CAD or a subject at risk for a cardiovascular event are also provided. The methods include using the level of detected metabolite in the subject to develop a treatment plan based on the risk of inherited cardiovascular disease in the subject. The plan may include diet, exercise and pharmaceutical treatment options.
In some embodiments, there is provided a method of developing a treatment plan for a subject comprising: (a) detecting in a sample from the subject the level of each metabolite in a group of metabolites consisting of C5-DC, C6-DC, C8:l-OH/C6:l-DC, and C8:1-DC; (b) comparing the level of each metabolite in the sample to a non-cardiovascular disease standard; and (c) determining that the subject has an increased risk of inherited cardiovascular disease when the level of the at least one metabolite is different from the standard; and (d) developing a treatment plan when an increased risk of inherited cardiovascular disease is determined in step (c).
In still another aspect, methods for assessing the risk of inherited cardiovascular disease in a subject are provided in which a sample is obtained from the subject. The sample is provided to a laboratory for detection of metabolite levels in the sample. The metabolites detected may be acylcamitines, amino acids, ketones, fatty acids or hydroxybutyrate. The laboratory returns a report indicating metabolite levels in the sample, which are indicative of the risk of cardiovascular disease in the subject.
In some embodiments, there is provided a method for assessing the risk of inherited cardiovascular disease in a subject, comprising: obtaining a sample from the subject; providing the sample to a laboratory for detection of each metabolite in a group of metabolites consisting of C5-DC, C6-DC, C8:l-OH/C6:l-DC, and C8:1-DC; receiving from the laboratory a report indicating metabolite levels in the sample; and determining that the subject has an increased risk of inherited cardiovascular disease when the level of each metabolite is different from a non-cardiovascular disease standard. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a set of graphs showing the receiver operating characteristic (ROC) curves for metabolite factors and CAD. ROC curves and measures of model fit (c-statistic) are presented for three models: a clinical model inclusive of traditional CAD risk factors (diabetes, hypertension, dyslipidemia, smoking, BMI, family history; and for the replication group, age, race and sex are also included) (black line); a model inclusive of all traditional risk factors plus metabolite factors 4 and 9 (gray line); and a model inclusive of all traditional risk factors plus all metabolite factors (dashed black line). The top graph shows the initial group and the bottom graph shows the replication group.
Figure 2 is a set of graphs showing the cox proportional hazards model for predictive capability of metabolite Factor 8 for cardiovascular events. Unadjusted (left panel) and adjusted (right panel) survival curves (adjusted for BMI, severity of CAD, hypertension, dyslipidemia, diabetes, smoking, family history, ejection fraction, serum creatinine, subsequent CABG, age, race and sex) are presented for metabolite factor 8.
Figure 3 is a pedigree of the eight multiplex GENECARD families. Black filled in symbols signify affected with premature CAD; smaller gray circles signify blood profiling performed for this study. Note that the majority of the family members profiled are as-of-yet unaffected offspring of the original affected-sibling pairs.
Figure 4 is a graph showing the heritabilities of conventional metabolites. The Y-axis is the negative loglO of the p-value for the heritability estimate (X-axis). Error bars around heritability point estimates are in light grey.
Figure 5 is a graph showing the heritabilities of amino acids and free fatty acids. Displayed are heritabilities of amino acids and free fatty acids. The Y-axis is the negative loglO of the p-value for the heritability estimate (X-axis). Error bars around heritability point estimates are in light grey.
Figure 6 is a graph showing the heritabilities of acylcarnitines. The Y-axis is the negative loglO of the p-value for the heritability estimate (X-axis). Error bars around heritability point estimates are in light grey.
DETAILED DESCRIPTION
Metabolomics, the study of small-molecule metabolites, may be useful for diagnosis of human disease. Studies have demonstrated heritability of metabolites in plants and mice. As described in the Examples, metabolite profiles are heritable in human families with early-onset CAD, suggesting that the known heritability of CAD may be mediated at least in part through metabolic components measurable in blood. The Examples describe quantitative profiling of 69 metabolites, including acylcamitine species (byproducts of mitochondrial fatty acid, carbohydrate and amino acid oxidation), amino acids and conventional metabolites such as free fatty acids, ketones and β-hydroxybutyrate, in participants enrolled in the Duke CATHGEN biorepository and in families selected from the Duke GENECARD study. The capability of metabolite profiles to assess the risk of cardiovascular disease in a subject is provided herein. The Examples demonstrate that the levels of particular metabolites, alone or in combination, discriminate the likelihood of developing CAD, the presence of CAD and the risk of subsequent cardiovascular events.
Methods of assessing or predicting risk of cardiovascular disease in a subject are provided. The methods include detecting the level of at least one metabolite in a sample from the subject. The amount or relative level of the metabolite may be detected. The metabolites detected may be acyl carnitines, amino acids, ketones, free fatty acids (FFA), or hydroxybutyrate. The level of the metabolite in the sample from the subject is then compared to a standard to assess the risk of cardiovascular disease. The standard may be an empirically derived number for each metabolite indicating a normal range and/or a range indicative of cardiovascular disease or may be direct comparison to the levels of metabolite in individuals with known cardiovascular disease status.
Methods for assessing the risk of cardiovascular disease in a subject by obtaining a sample from the subject and providing the sample to a laboratory for detection of metabolite levels in the sample are also provided. As above, the metabolite detected by the laboratory may include acylcamitines, amino acids, ketones, fatty acids and hydroxybutyrate. A report indicating metabolite levels in the sample is then received from the laboratory. The report indicates the level of the metabolite in the subject and the level can be used to compare to standard values to indicate the risk of cardiovascular disease in the subject.
The risk of cardiovascular disease includes assessing the risk of a subject without CAD developing CAD over time due to heritable factors, assessing the presence or absence of CAD in a subject and assessing the risk of having a cardiovascular event. Cardiovascular events include myocardial infarction, stroke and death.
Subjects may be any mammal, suitably the subject is human. Subjects identified as having or at risk of developing CAD may be further assessed to determine their risk of a cardiovascular event using the methods provided herein. The methods may be used to help diagnose the presence of CAD in a non-invasive fashion and/or to develop a treatment plan for subjects identified as at risk for CAD, having CAD or at risk for a cardiovascular event. The treatment plan may include provision of dietary, exercise, and pharmaceutical therapies to the subject. A cardiovascular event includes, but is not limited to, myocardial infarction (MI), stroke and death.
The metabolite may be detected using a variety of samples, several of which will be apparent to those skilled in the art. In the Examples, peripheral blood was obtained from the subject and processed in order to detect the level of metabolites in the subject. Other tissues or fluids from the subject may also be used, including but not limited to blood, plasma, urine, serum, saliva, and tissue biopsies.
Any method may be used to detect the metabolite. Suitably the method is quantitative such that the level or amount of the metabolite in the subject or a sample from the subject may be determined. In the Examples, the level of the metabolites was detected by mass spectrometry. Other methods of measurement may be used, including nuclear magnetic resonance (NMR). The metabolites may also be detected using colorimetric or fluorometric assays based on detection of the metabolite by an assay such as a binding or enzymatic assay.
Any suitable assay method for the metabolites may be used. Such methods will be apparent to those skilled in the art. The level of the metabolite in the subject may be reported as ng/ml of metabolite in blood or tissue, by the mM or μΜ concentration of the metabolite in the blood or tissue or by using arbitrary units to show relative levels amongst subjects. In the Examples, the mM or pM of metabolite in the blood are reported.
In some embodiments, detection of a single metabolite is sufficient to assess risk of cardiovascular disease. In other embodiments, 2, 3, 4, 5, 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 or 65 metabolites may be detected and used in the methods to assess the risk of cardiovascular disease. The metabolites detected may be related in a factor by principal component analysis of a population of subjects. The factors, or groups of metabolites, useful for assessing heritability of CAD and for the presence of CAD or risk of having a cardiovascular event are presented in the Examples below.
The level of metabolite in the subject is used to determine whether the subject has CAD, risk of the subject developing CAD and/or the risk of the subject experiencing a cardiovascular event in the future. The level of risk determination may be based on a standard level of the metabolite present in the blood. Such a standard is used for the relationship between HDL and LDL cholesterol measurements in which risk for CAD is predicted when cholesterol levels reach certain level in the blood after fasting and the ratio of HDL to LDL is beyond standard limits. Such standards are generally developed based on a large population study. Alternatively, the determination of risk may be based on direct comparison to one or more control subjects. For example, a set of control subjects lacking CAD and with no cardiovascular events in the two years following sample procurement and a set of control subjects with CAD and with or without a cardiovascular event in the two years following sample procurement could be used as a comparison.
The risk of cardiovascular disease in the subject may be expressed in relative terms. For instance a normal level of a metabolite may be referred to as 1.0 in subjects at low to average risk for cardiovascular disease such as CAD or a cardiovascular event. Any numbers below 1.0 could indicate the subject has a lower risk than the general population risk. A number greater than 1.0 would indicate that the subject has a greater than average risk level and the actual number could relate to the level of risk. For example, a subject whose metabolite level is 2.0 may be two times as likely to experience a cardiovascular event in the next two years as compared to an average individual.
The assessment of risk of cardiovascular disease, including CAD or a future cardiovascular event, includes but is not limited to, developing a risk profile. The assessment or prediction may indicate that the subject is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 750% or 1000% more likely to have or develop a cardiovascular disease, such as CAD or have cardiovascular event, than a control subject. A control subject is an individual that does not have CAD and possesses levels of the metabolite that do not correlate with an increased risk of CAD or a cardiovascular event.
The metabolites predictive of risk of developing cardiovascular disease CAD include metabolites involved in many of the major pathways of lipid, protein and carbohydrate metabolism. Thus, the acylcamitines include acetyl carnitine (C2), a by-product of glucose, fatty acid and amino acid metabolism, Propionyl carnitine (C3) and Isoveleryl carnitine (C5), which provide information on amino acid catabolism, the dicarboxylated acylcamitine, which report on peroxisomal fatty acid metabolism, and the medium-long chain acylcamitines, which are intermediates in long-chain fatty acid beta-oxidation. The amino acids serve as important intermediates in protein turnover and catabolism and the ketones are an index of fatty acid beta-oxidation. Table 1 below shows the short and full-names of the metabolites tested in the Examples. Table 2 shows the biological functions, if available, of each of the tested metabolites.
Table 1. Nomenclature and Intra-Individual Variability of Metabolites. Metabolite short names, full names, and measures of intra-individual variability are presented.
Table 2. Biological functions of the metabolites measured. By measuring conventional metabolites such as fatty acids, ketones and beta-hydroxybutyrate, a large panel of acylcamitines and fifteen of the biologically relevant amino acids, the panel of metabolites surveyed report on the major pathways of lipid, protein and carbohydrate metabolism. This table displays biological functions (when available) of each of the individual metabolites measured.
Methods of predicting the risk of a cardiovascular event (death or myocardial infarction) in a subject by detecting at least one metabolite in the subject are also provided. The metabolites predictive of risk of a cardiovascular event are presumed products of peroxisomal fatty acid metabolism, in particular the short-chain dicarboxyl acylcamitines, and citrulline. The specific metabolites are listed in Table 9 of the Examples and are identified as factor 8. Table 10 shows the individual metabolites within Factor 8 and provides the Factor load data for each metabolite. The data in the Examples demonstrate that citrulline and the short-chain dicarboxyl acylcamitines are predictive of the risk of a cardiovascular event.
Individual metabolites may also be predictive of the risk of a cardiovascular event. These metabolites include Gly, Ala, Ser, Pro, Met, His, Phe, Tyr, Asx, Glx, Ornithine, Citrulline, arg, C2, C3, C4:C14; C5:l, C5, C4:OH, C14-DC:C4DC, C5-DC, C6-DC, C10:3, CIO, C10-OH:C8DC, 02:1, 02, C12-OH:C10DC, C14:1-0H, C14-OH:C12-DC, 06, C16-OH/C14-DC, 08:2, C18-OH/C16-DC, C20, C20:1-OH/C18:1-DC, C20-OH/C18-DC, C8:l-OH/C6:l-DC, C8:1-DC, 06:1, C16:l-OH/C14:l-DC, C20:4, FFA, HBUT, and Ket.
In particular, the levels of citrulline, C5-DC, C6-DC, C8:l-OH/C6:l-DC, and C8:1-DC are predictive of cardiovascular events. In addition, the levels of ornithine, citrulline, C5, 04-DC:C4DC, C5-DC, C6-DC, C10-OH:C8DC, C8:l-OH/C6:l-DC, C8:1-DC, C20:4 and FFA are also useful for assessing the risk of a cardiovascular event.
Methods of assessing the presence and/or extent of CAD in a subject by detecting the level of at least one metabolite in a sample from the subject are also provided. The metabolites useful for assessing the presence of CAD are medium-chain acylcamitine, a branched chain amino acid or associated metabolite, or a metabolite associated with the urea cycle.
The specific metabolites are listed in Table 6, 7 and 8 of the Examples and are identified as factors 1, 4, and 9 in Table 9. Table 10 shows the individual metabolites within Factors 1, 4 and 9 and provides the Factor load data for each metabolite. Only those metabolites with factor loads greater than or equal to 0.04 are included in the factor.
Individual metabolites may also be predictive of the risk of a cardiovascular event. These metabolites include Pro, Leu/Ile, Met, Val, Glx, Citrulline, C2, C3, C4:Ci4; C5, C8, C8:l-OH/C6:l-DC, 00:1, 04:2, C14:1-0H, 06:2, 06:1, 06:2, 06:1, 06:1-0H/C14:1-DC, C18-OH/C16-DC, HBUT, and Ket. In particular, the levels of Leu/Ile, Glx, C2, 04:1-OH and C16:l-OH/C14:l-DC are indicative of the presence of CAD in a subject. Increased levels of Leu/Ile or Glx as compared to normal controls or a normal standard are indicative of CAD in the subject. Decreases levels of C2, C14:1-0H and C16:l-OH/C14:l-DC are indicative of the presence of CAD in a subject. A level of Leu/Ile greater than 165mM, 170mM or 175mM is indicative of coronary artery disease. A level of Glx greater than 127mM, 128mM, 129mM, 130mM, 132mM, 135mM or 140mMis indicative of coronary artery disease. A level of C14:1-0H less than 0.014μΜ, 0.013μΜ or 0.012μΜ is indicative of coronary artery disease. A level of C16:1-0H/C14:1-DC less than 0.009μΜ, 0.0089μΜ, or 0.0088μΜ is indicative of coronary artery disease.
Methods of assessing the likelihood of developing CAD in a subject by detecting the level of at least one metabolite in a sample from the subject are also provided. The metabolites useful for assessing the likely development of CAD are the short- and medium-chain acylcarnitine metabolites, branched chain amino acids and urea cycle related metabolites.
The specific metabolites are listed in Table 14 of the Examples. Table 15 shows the individual metabolites within the identified Factors. Only those metabolites with factor loads greater than or equal to 0.04 are included in the factor. Individual metabolites may also be predictive of the risk of a cardiovascular event. These metabolites include ketones, arg, ornithine, citrulline, glx, ala, val, leu/ile, pro, C2, 04:1, 08:1, C5:l, C4-i4, 08, 00:1 and FFA.
The Examples below are meant to be illustrative and not to limit the scope of the invention.
EXAMPLES
Example 1: Association of Metabolites with CAD and Risk of Cardiovascular Events
Methods
Study Sample
The CATHGEN biorepository consists of subjects recruited sequentially through the cardiac catheterization laboratories at Duke University Medical Center (Durham, NC). After informed consent, blood was obtained from the femoral artery at time of arterial access for catheterization, immediately processed to separate plasma, and frozen at -80°C. All subjects were fasting for a minimum of six hours prior to collection. Clinical data were provided by the DDCD, a database of patients undergoing cardiac catheterization at Duke University since 1969. Medication data were collected for medications used chronically, i.e. medications at admission (inpatients) or from a clinic note within one month prior (outpatients). Follow-up data, including occurrence of myocardial infarction (MI) and death were collected at six months after catheterization, then annually thereafter. Vital status was confirmed through the National Death Index. The indication for catheterization for all subjects was clinical concern for ischemic heart disease. Patients with severe pulmonary hypertension or organ transplant were excluded.
To evaluate the discriminative capability of metabolites for CAD, two independent case-control groups were constructed: ‘initial’ (174 CAD cases and 174 CAD-free controls); and ‘replication’ (140 CAD cases and 140 CAD-free controls). For the initial group, sequential cases meeting inclusion criteria were selected: CADindex >32 (at least one coronary artery with >95% stenosis) and age-of-onset <55 years. CADindex is a numerical summary of angiographic data. (Smith et al., Circulation 1991;84[5 Suppl], 111:245-253.) Age-of-onset was defined as age at first MI, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or age at first catheterization meeting CADindex threshold. Sex- and race-matched controls meeting the following criteria were selected: CADindex <23; no coronary artery with >50% stenosis; age-at-catheterization >61 years; and no history of MI, PCI, CABG, or transplant. Given the differences in age based on these criteria, results could be confounded by age. Therefore, for the replication group, sequential cases and controls meeting the same inclusion criteria were selected, but the criterion of age-of-onset (cases) or age-at-catheterization (controls) was removed and cases/controls were not matched. This allowed generalizability of findings to a representative population of patients referred for catheterization. Analyses were also performed by constraining CAD cases to those with a previous history of MI (A=86 cases in initial, A=61 cases in replication).
To evaluate the capability of metabolites to predict risk of subsequent cardiovascular events, an ‘event’ group was constructed, combining CAD cases from the initial and replication groups (‘event’ group, A-3 14); of these, 74 individuals suffered death or MI during follow-up. To validate findings for the association of metabolites with risk of cardiovascular events, profiling was performed in an independent cardiovascular event case-control group (‘event-replication’) composed of unique individuals from CATHGEN meeting the following criteria: ejection fraction >40%; no history of PCI or CABG; and no subsequent CABG. Among these, event cases (A=63) suffered death or MI, or had PCI with acute coronary syndrome within two years after catheterization; controls (N= 66) were event-free, with at least two years of follow-up, and were matched to cases on age, race, sex and CADindex.
The Duke Institutional Review Board approved the protocols for CATHGEN and the current study. Informed consent was obtained from each subject.
Metabolite Measurements
Fasting plasma samples were used for quantitative determination of targeted levels for 45 acylcarnitines, 15 amino acids, five conventional analytes (total, low-density[LDL] and high-density lipoprotein [HDL] cholesterol, triglycerides and glucose), ketones, β-hydroxybutyrate, total free fatty acids and C-reactive protein [CRP] (Table 1). Methodology and coefficients of variation for each assay have been reported. (Shah et al., Mol Syst Biol 2009;5:258 and Newgard et al., Cell Metab 2009;9(4):311-26.) The laboratory (Sarah W. Stedman Nutrition and Metabolism metabolomics/biomarker core laboratory) was blinded to case-control status and cases/controls were randomly distributed.
Standard clinical chemistry methods were used for conventional metabolites with reagents from Roche Diagnostics (Indianapolis, IN), and for free fatty acids (total) and ketones (total and β-hydroxybutyrate) with reagents from Wako. All assays were performed on a Hitachi 911 clinical chemistry analyzer.
For mass spectroscopy (MS)-profiled metabolites (acylcarnitines, amino acids) the following protocol was used. (An et al., Nat Med 2004; 10(3):268-74 and Chace et al., Clin
Chem 1995;41(l):62-8.) Proteins were first removed by precipitation with methanol. Aliquoted supernatants were dried, and then esterified with hot, acidic methanol (acylcarnitines) or «-butanol (amino acids). Analysis was done using tandem MS with a Quattro Micro instrument (Waters Corporation, Milford, MA). Quantification of the “targeted” intermediary metabolites was facilitated by addition of mixtures of known quantities of stable-isotope internal standards (Table 3). Leucine/isoleucine (LEU/ILE) are reported as a single analyte because they are not resolved by our MS/MS method, and include contributions from a//o-isoleucine and hydroxyproline. Under normal circumstances these isobaric amino acids contribute little to the signal attributed to LEU/ILE. In addition, the acidic conditions used to form butyl esters results in partial hydrolysis of glutamine to glutamic acid and of asparagine to aspartate. Accordingly, values that are reported as GLU/GLN (GLX) or ASP/ASN (ASX) are not meant to signify the molar sum of glutamate and glutamine, or of aspartate and asparagine, but rather measure the amount of glutamate or aspartate plus the contribution of the partial hydrolysis reactions of glutamine and asparagine, respectively. Biological annotation is included in Table 2 above.
Table 3. Internal spiked standards for acylcarnitine and amino acid measurements.
Statistical Analysis
Metabolite levels reported as “0” (i.e., below the lower limits of quantification (LOQ)) were given a value of LOQ/2. Metabolites with >25% of values as “0” were not analyzed (five acylcamitines). All metabolites were natural log-transformed to approximate a normal distribution. For analysis of CAD status, generalized linear regression models were used to assess differences in metabolite levels between CAD cases and controls, both unadjusted and adjusted for traditional CAD risk factors not constrained by matching: diabetes, hypertension, dyslipidemia, body-mass-index (BMI), family history of CAD, and smoking. Analyses of the replication group were further adjusted for race, sex and age. With log transformation, all significant metabolites showed a normal distribution (Kolmogorov-Smirnov test P >0.01), except valine, ketones, and C8, C8:l-OH/C6:l-DC, 00:1, 04:2, 06:1, C16:l-OH/C14:l-DC, and C18-OH/C16-DC acylcamitines. Visual inspection of the distributions suggested a grossly normal distribution. Regardless, we performed sensitivity analyses using non-parametric Wilcoxon tests, showing similar results as the semi-parametric linear models, except for valine and 04:2 acylcarnitine, both of which were not significant in linear regressions (p=0.10 and p=0.06, respectively), but were significant with these nonparametric tests (p=0.05 and p=0.008). Analyses were also stratified by diabetes and smoking.
In exploratory analyses, multivariable models were further adjusted for medication classes (beta-blockers, statins, diabetes medications, aspirin, angiotensin-converting-enzyme inhibitors, nitrates, clopidogrel and diuretics), use of pre-procedural sedation, and continuous intravenous heparin use at time of catheterization. The CATHGEN protocol requires sample collection prior to supplemental heparin administration during catheterization. Therefore, adjustment for continuous intravenous heparin use at time of catheterization addresses differences related to heparin. Only 66% of individuals had medication data, hence medications were coded as a discrete variable: not on medication, missing, and on medication.
Given that metabolites reside in overlapping pathways, correlation of metabolites is expected. We used principal components analysis (PCA) to reduce the large number of correlated variables into uncorrelated factors. Factors with higher “eigenvalues” account for larger amounts of variability within the dataset. Factors with an eigenvalue >1.0 were identified and varimax rotation performed to produce interpretable factors. Metabolites with a factor load >|0.4| were reported as composing a factor. See Table 10. Scoring coefficients were constructed from the initial group and used to calculate factor scores for each individual (weighted sum of the standardized metabolites within that factor, weighted on the factor loading for each metabolite), and were also applied to the replication group. Generalized linear regression models were used to assess the difference in factor scores between cases and controls. All factors were normally distributed (Kolmogorov-Smimov test P>0.01), except for factors 7- 9; visual inspection showed a grossly normal distribution. Non-parametric Wilcoxon tests for these factors showed the same results as linear models.
To further assess the independent capability of metabolite profiles to discriminate CAD cases from controls, multivariable logistic regression models were constructed; in these models, CAD risk factors (BMI, dyslipidemia, hypertension, diabetes, family history, smoking) were forced into the model, then metabolite factors were added. Receiver operating curves (ROC) were constructed and measures of model fit calculated. Nonparametric analysis for comparison of the areas under these curves was performed using previous methods. (DeLong et al., Biometrics 1988;44(3):837-45.)
For analysis of subsequent cardiovascular events, cases from initial and replication groups were pooled (‘event’ group). The relationship between metabolite factors and time-to-occurrence of death/MI was assessed using Cox proportional hazards (unadjusted and adjusted for BMI, dyslipidemia, hypertension, diabetes, family history, smoking, age, race, sex, creatinine, ejection fraction and CADindex). The assumption of proportional hazards was met. For replication in the ‘event-replication’ group, scoring coefficients from PCA-derived factors constructed in the initial CAD group were used to calculate factor scores in the event-replication group; logistic regression was used to assess the association between factors and case/control status (unadjusted and adjusted for BMI, dyslipidemia, hypertension, diabetes, family history, smoking, creatinine, and ejection fraction).
As all analyses were exploratory in nature and given co-linearity of the metabolites, two-sided p-values unadjusted for multiple comparisons are presented; however, results interpreted in the context of Bonferroni correction are reported. Nominal statistical significance was defined as P<0.05. Bonferroni corrected p-values were P<0.0007 (individual metabolites) and P<0.004 (factors). Statistical analyses were performed by D.R.C. and S.H.S. using SAS version 9.1 (Cary NC).
Results
Patient populations
Population characteristics for the initial (174 early-onset CAD cases, 174 matched controls) and replication groups (140 CAD cases, 140 controls) are displayed in Table 4, and for the event-replication group in Table 5.
Table 4. Baseline Clinical Characteristics of Initial and Replication Groups.
Table 5: Baseline Clinical Characteristics of the Event Replication Group.
for ditfsrence between subjects with events anti eveni-free crottfrofe.
Association of Individual Metabolites with CAD
Levels of several amino acids were different between cases and controls in the initial group (Table 6), including the branched-chain amino acids leucine/isoleucine (P<0.0001) and valine (P=0.007), glutamate/glutamine (P<0.0001), proline (P=0.04) and methionine (P=0.05). Levels of several acylcamitines were also different between cases and controls in the initial group, including the C16 acylcamitines (C16:l, P=0.006; C16:l-OH/C14:l-DC, P=0.004; C16:2, P=0.05; and C18-OH/C16-DC, P=0.003), and C4:Ci4 (P=0.009), C8 (P=0.009), C8:l-OH/C6:l-DC (P=0.003), and C10:l (P=0.002) acylcamitine (Table 6). For most metabolites, these differences persisted after adjustment for CAD risk factors.
Table 6. Association of Individual Metabolites with CAD. Means and standard deviations for metabolites significantly different between cases and controls in the initial group are presented. Results for these analytes in the replication group are also presented. All values are in millimolar for amino acids and micromolar for acylcamitines. Analytes in bold show consistent association across both datasets (with consistent direction of effect)._
*adjusted for diabetes, hypertension, smoking, dyslipidemia, family history of CAD, BMI. •[adjusted for age, race, sex, diabetes, hypertension, smoking, dyslipidemia, family history of CAD, BMI
Several of these metabolites were also significant in the replication group in adjusted analyses (with similar direction of effect), including the amino acids leucine/isoleucine and glutamate/glutamine, and the long-chain acyl carnitines C14:l-OH and C16:l-OH/C14:l-DC (Table 6). In unadjusted analyses, these metabolites, amino acids methionine and proline, and C16:2 and C16:1 acylcamitine were significant in both groups.
Further adjustment for lipids (total, LDL, and HDL cholesterol and triglycerides) resulted in similar results, although with attenuation of association for LEU/ILE in the initial group (Tables 7 and 8). Analyses stratified by diabetes suggested some heterogeneity of association by diabetes. For example, LEU/ILE and C16:1-OU/C14:1-DC showed stronger association in non-diabetics. Analyses stratified by smoking suggested no difference in smokers and non-smokers.
Table 7. Association of Individual Metabolites with CAD in the Initial Group. Means and standard deviations for all individual metabolites for the overall initial group, as well as stratified by CAD, are presented. All values are in millimolar for amino acids and micromolar for acylcarnitines. P-values are for the association between metabolites and CAD in unadjusted and adjusted analyses. Analytes in bold show consistent association across both datasets in adjusted analyses (with consistent direction of effect).
"s^i/sted for diabetes, ttyparisminn, sfimxing, afw^&tensa, family tmtaty of CAD, 3ML fadjusted for diabetes, hypertension, smoking, dyslipidemia, family history of CAD, BMI, and total, LDL, HDL cholesterol and triglycerides.
Table 8. Association of Individual Metabolites with CAD in the Replication Group.
Means and standard deviations for all individual metabolites for the overall replication group, as well as stratified by CAD, are presented. All values are in millimolar for amino acids and micromolar for acylcarnitines. P-values are for the association between metabolites and CAD in unadjusted and adjusted analyses. Analytes in bold show consistent association across both datasets in adjusted analyses (with consistent direction of effect).
*edjtfstB<} for age, race, sex, tfiateies, hypotension, smoking, dysUpkiemia, family hssiary a! CAD, S&Jf fadjusted for age, race, sex, diabetes, hypertension, smoking, dyslipidemia, family history of CAD, BMI, and total, LDL, HDL cholesterol and triglycerides.
Unbiased Principal Components Analysis PCA identified 12 factors comprised of collinear metabolites (Table 9), grouping in biologically plausible factors. Three factors were significantly different between cases and controls in the initial group in adjusted analyses: factor 1 (medium-chain acylcarnitines), factor 4 (branched-chain amino acids and related metabolites), and factor 9 (arginine, histidine, citrulline, Ci4-DC:C4DC). Of these factors, two factors (4 and 9) remained significant in the replication group. Factor 1 was only weakly significant in the replication group (unadjusted P=0.15, adjusted P=0.03). The factor load for each metabolite is presented in Table 10.
Table 9. Principal Components Analysis. Results of unbiased principal components analysis (PCA) are presented. Factors were constructed using the initial group; scoring coefficients from this PCA were used to calculate factor scores for the initial and replication groups. P-values for the difference in the mean value of the factors between cases and controls for the initial and replication groups are presented.
*Analytes with a factor load >|0.4| for that factor are listed, in order of magnitude of load for that factor; analytes with a negative factor load for that factor are annotated with a (-). **Proportion of variance explained by that factor, f adjusted for diabetes, hypertension, smoking, dyslipidemia, family history of CAD, BMI; replication group results are additionally adjusted for age, race and sex.
Table 10. Factor Loads of Individual Metabolites on Factors Identified from PCA on the Initial Group.
Further adjustment for lipids showed continued association with CAD, although Factor 4 was not significant in the initial group (initial group: factor 1, P=0.0002; factor 4, P=0.59; factor 9, P=0.02; replication group: factor 1, P=0.01; factor 4, P=0.02; factor 9, P=0.004). Although we adjusted for diabetes, given studies showing relationships between metabolites with insulin resistance, we further adjusted the base multivariable model for fasting glucose. These analyses revealed a continued significant association with CAD (initial group: factor 1, P=0.02; factor 4, P=0.02; factor 9, P=0.003; replication group: factorl, P=0.03; factor 4, P=0.05; factor 9, P=0.02).
Stratified analyses suggested stronger association between factors 4 and 9 with CAD in non-diabetics as compared with diabetics (Table 11), with minimal or no discernable signal in diabetics, but no consistent differences in association with CAD by smoking (Table 12).
Table 11. Association of PCA Derived Metabolomic Factors with CAD, Stratified by Diabetes. P-values for the association of PCA-derived metabolomic factors with CAD, stratified by a medical history of diabetes, are presented. Unadjusted p-values and p-values adjusted for hypertension, smoking, dyslipidemia, family history and BMI (and also for age, race and sex in the Replication Group) are presented.
Table 12. Association of PCA Derived Metabolomic Factors with CAD, Stratified by Smoking. P-values for the association of PCA-derived metabolomic factors with CAD, stratified by smoking (currently smoking or not), are presented. Unadjusted p-values and p-values adjusted for diabetes, hypertension, dyslipidemia, family history and BMI (and also for age, race and sex for the Replication Group) are presented.
Additional adjustment for ten classes of medications had minimal influence on the relationship between factors and CAD in the initial group (factor 1, adjusted P=0.009; factor 4, P=0.03; factor 9, P=0.003), but were no longer significant in the replication group (factor 1, P=0.02; factor 4, P=0.19; factor 9, P=0.14). We also performed similar analyses restricted to those individuals with available medication data, in the combined datasets to optimize power (N=416). These results showed continued association between factors 4 and 9 with CAD, although attenuated (factor 4: unadjusted model, p=0.0009; model adjusted for CAD risk factors, P=0.03; model adjusted for CAD risk factors and medications, P=0.05; factor 9: unadjusted model, P=0.0003; model adjusted for CAD risk factors, P=0.002; model adjusted for CAD risk factors and medications, P=0.007).
Results presented are unadjusted for multiple comparisons. We used PCA to account for co-linearity of metabolites. Of the individual metabolites, only glutamate/glutamine would survive Bonferroni correction. Factors 4 and 9 would survive Bonferroni correction at the level of factors (P<0.004).
Association of Metabolite Profiles with Prevalent Myocardial Infarction
To examine association of these metabolites with a more severe phenotype, we evaluated the relationship of the PCA-derived factors in cases with a prior history of MI compared with controls free of CAD (initial group N= 86 MI cases, replication group A-61 MI case). The two factors (4 and 9) that were associated with CAD were also associated with prior MI in both groups (Table 9).
Assessment of Model Fit and ROC Curves for CAD
To further quantify the independent association of metabolite factors with CAD, logistic regression models were constructed: (1) clinical model; (2) clinical model plus factors 4 and 9; and (3) clinical model plus all metabolite factors. Factors 4 and 9 were independently associated with CAD in both the initial group (factor 4: odds ratio [OR] 1.42; 95% Cl, 1.09 to 1.84, P=0.01; factor 9: OR 0.69, 95% Cl, 0.53 to 0.90, P=0.006) and the replication group (factor 4: OR 1.42; 95% Cl 1.06 to 1.89, P=0.02; factor 9: OR 0.67; 95% Cl 0.48 to 0.92, P=0.01). Measure of model fit and ROC curves (Figure 1) in the initial group showed modestly greater discriminative capability for models containing factors 4 and 9 (c-statistic 0.778), with some improvement with addition of all factors (c-statistic 0.804), above the model containing only clinical variables (c-statistic 0.756; P=0.06 for comparison of clinical model to clinical model plus factors 4 and 9; P=0.003 for comparison of clinical model to clinical model plus all factors). In the replication group, there was a slightly higher c-statistic with the addition of factors 4 and 9 to the clinical model (c-statistic 0.773) than for the clinical model alone (c-statistic 0.743), but more dramatic improvement with addition of all factors (c-statistic 0.874; P=0.04 for comparison of clinical model to clinical model plus factors 4 and 9; and P<0.0001 for comparison of clinical model to clinical model plus all factors).
Given it is standard of care to measure lipids in patients in whom a diagnosis of CAD is being considered, and that CRP is a recognized biomarker of cardiovascular disease, we reconstructed these models including lipids and CRP. These analyses revealed a higher clinical model fit in both initial and replication groups (c-statistic 0.842 and 0.778, respectively). The addition of factors 4 and 9 to the clinical model inclusive of lipids and CRP resulted in no improvement in the discriminative ability of the model in the initial group (c-statistic 0.848, P=0.31 for comparison with clinical model), with some improvement with addition of all factors (c-statistic 0.865, P=0.01 for comparison with clinical model). However, the magnitude of improvement in the clinical model with addition of metabolite factors remained similar and large in the replication group (c-statistics: clinical model inclusive of lipids and CRP, 0.778; clinical model + factors 4 and 9, 0.799, P=0.08; clinical model + all metabolite factors, 0.900, P=0.0001 for comparison with clinical model). Metabolite Factors and Risk of Subsequent Cardiovascular Events
During a median of 2.72 years of follow-up, 74 of 314 CAD cases had an incident cardiovascular event. In unadjusted comparisons, factor 8 (short-chain dicarboxylacylcarnitines) was highly associated with occurrence of death or MI (Figure 2; highest versus lowest tertile hazard ratio [HR] 2.50; 95% Cl, 1.47 to 4.17; P=0.0008; highest versus middle tertile HR 2.33; 95% Cl, 1.39 to 3.85; P=0.002). The strength of this association was somewhat attenuated after adjustment for CAD risk factors, CADindex, age, race, sex, ejection fraction, creatinine and treatment with CABG after catheterization (highest versus lowest tertile: HR 1.67; 95% Cl, 0.88 to 3.13; P=0.11; highest versus middle tertile: HR 1.89; 95% Cl 1.09 to 3.33; P=0.03). Factor 1 was also associated with the occurrence of death/MI in unadjusted comparisons (highest versus lowest tertile HR 1.85; 95% Cl, 1.06 to 3.23; P=0.03; highest versus middle tertile HR 1.79; 95% Cl, 1.02 to 3.03; P=0.04), but was no longer significant after adjustment (P=0.14 and 0.05, respectively).
To validate these findings, we performed metabolomic profiling in an independent case-control dataset (‘event-replication’ group). In this group, factor 8 was associated with cardiovascular events (unadjusted OR 1.52; 95% Cl, 1.08 to 2.14; P=0.01; adjusted OR 1.82; 95% Cl, 1.08 to 3.50; P=0.03), with higher scores in cases who suffered subsequent cardiovascular events versus event-free controls. Individual metabolites within the factor were also significantly different (P<0.05) between cases and controls, with a similar direction of effect as observed in the original ‘event’ dataset.
This example demonstrates that peripheral blood metabolite profiles are independently associated with the presence of CAD, and add to the discriminative capability for CAD compared with models containing only clinical variables. Further, we report a specific metabolite cluster that independently predicts subsequent cardiovascular events in individuals with CAD.
Example 2: Heritability of CAD MATERIALS AND METHODS
Study Population. The GENECARD study enrolled 920 families to perform affected-sibling-pair linkage for identification of genes for early-onset CAD (before age 51 for men, age 56 for women) (Hauser et al., 2003, Am Heart J, 145, 602-613). Families with at least two siblings each of whom met the criteria for early-onset CAD (before age 51 for men, age 56 for women) were recruited. Unaffected family members were defined as no clinical evidence of CAD and age greater than 55 years for men (greater than 60 years for women). From this cohort, we selected eight representative families we believed would be particularly informative, based on availability of a relatively large number of family members and a heavy burden of CAD in the proband and surrounding generations (Figure 3). These families were recontacted; the affected-sibling-pair and family members not previously enrolled were ascertained regardless of CAD, focused on offspring of the affected-sibling-pair. This ascertainment strategy was based on the hypothesis that if abnormalities in metabolic profiles preceded development of CAD in these families, that significant concordance of metabolite levels within families would be evident even in the absence of overt CAD in the offspring. Sample collections within a given family were done at several different times and at different locations, by a single experienced phlebotomist. Blood samples were promptly processed after collection via peripheral venous phlebotomy (within minutes), frozen as soon as possible thereafter (at most within 12 hours with the majority of samples being frozen within 1-2 hours of collection), and stored as plasma samples in EDTA-treated tubes at -80°C. Samples were collected as often as possible in a fasting state; however, the consistency of this could not be determined. Institutional Review Boards approved study protocols; informed consent was obtained from each subject.
Biochemical measurements. Frozen plasma samples were used to quantitatively measure targeted metabolites, including 37 acylcarnitine species, 15 amino acids, nine free fatty acids and conventional analytes, ketones and C-reactive protein (CRP). Sample preparation and coefficients of variation have been reported (Haqq el a/., 2005 Contemp Clin Trials, 26, 616-625). The laboratory was blinded to family identifiers and case-control status. Assay ranges are 0.05- 40 micromolar (μΜ) (acylcarnitines); 5-1000 μΜ (amino acids); and 1-1000 mmol/L (fatty acids). For simplicity, the clinical shorthand of metabolites is used (Table 1). Intra-individual variability was assessed in samples from five individuals for which repeat profiling was performed on the same sample on five separate days. Coefficients-of-variation and correlation confirmed minimal inter-assay variability (Table 1).
Conventional metabolite analysis. Standard clinical chemistry methods were used for conventional metabolites, including glucose, total cholesterol, high-density-lipoprotein (HDL)- and low-density-lipoprotein (LDL) cholesterol, and triglycerides with reagents from Roche Diagnostics (Indianapolis, IN); and free fatty acids (total) and ketones (total and 3-hydroxybutyrate) with reagents from Wako (Richmond, VA). All measurements were performed using a Hitachi 911 clinical chemistry analyzer.
Acylcarnitines and amino acids. Proteins were first removed by precipitation with methanol. Aliquoted supernatants were dried, and then esterified with hot, acidic methanol (acylcarnitines) or «-butanol (amino acids). Acylcarnitines and amino acids were analyzed by tandem MS with a Quattro Micro instrument (Waters Corporation, Milford, MA). Thirty-seven acyl carnitine species and 15 amino acids in plasma were assayed by our previously described methods (Millington etal., 1990, JInheritMetab Dis, 13, 321-324;An et al., 2004, Nat Med, 10, 268-274;Wu etal., 2004, J Clin Invest, 113,434-440). Leucine/isoleucine (LEU/ILE) are reported as a single analyte because they are not resolved by our MS/MS method, and include contributions from a//o-isoleucine and hydroxyproline. Under normal circumstances these isobaric amino acids contribute little to the signal attributed to LEU/ILE. In addition, the acidic conditions used to form butyl esters results in partial hydrolysis of glutamine to glutamic acid and of asparagine to aspartate. Accordingly, values that are reported as GLU/GLN or ASP/ASN are not meant to signify the molar sum of glutamate and glutamine, or of aspartate and asparagine, but rather measure the amount of glutamate or aspartate plus the contribution of the partial hydrolysis reactions of glutamine and asparagine, respectively.
Free fatty acids. Free fatty acids were gently methylated using iodomethane and purified by solid-phase extraction (Patterson et al., 1999, J Lipid Res, 40, 2118-2124). Derivatized fatty acids were analyzed by capillary gas chromatography/mass spectrometry (GC/MS) using a Trace DSQ instrument (Thermo Electron Corporation, Austin, TX). Due to sample volume considerations, only 80 of the 117 individuals (five out of eight families) had free fatty acid measurements performed.
All mass-spectrometric analyses employed stable-isotope-dilution. Quantification of the foregoing “targeted” intermediary metabolites was facilitated by addition of mixtures of known quantities of stable-isotope internal standards to samples, from Isotec (St. Louis, MO), Cambridge Isotope Laboratories (Andover, MA) and CDN Isotopes (Pointe-Claire, Quebec, CN) (Table 3).
Heritability analysis. Heritabilities were calculated using the Sequential Oligogenic Linkage Analysis Routines (SOLAR) software version 4.0.7 (Almasy and Blangero, 1998, Am JHum Genet, 62, 1198-1211), which uses maximum-likelihood methods to estimate variance components, allowing incorporation of fixed effects for known covariates and variance components for genetic effects. This approach appropriately accounts for correlation between all family members and allows incorporation of extended pedigrees such as is present in the current study. The total variation is partitioned into components for additive genetic variance and environmental variance, as well as a residual (unexplained) variability. The program uses the pedigree covariance matrix
\ where Ω is the covariance matrix, Φ is the matrix of kinship values, iifk is the additive ·>. genetic variance, / represents the identity matrix, and ^is the random environmental variance (Almasy et al., 1998, supra). This model allows for complex pedigree data (i.e. beyond parent-offspring pairs) and hence, the resulting heritability estimates are more accurate than those obtained using only nuclear family members. For the current study, all sampled individuals from the pedigree were entered into the variance components models, including unaffected offspring, cousins, and married-in family members. Incorporation of married-in family members (i.e. genetically unrelated but with shared environment) allows for better estimation of the environmental component of intrafamilial clustering of traits.
Values considered outliers were excluded from heritability analyses, defined as values falling outside of the mean ±4SD (one-two outliers for each of 24 of the metabolites). Metabolite measurements below the lower limits of quantification (LOQ) were given a value of LOQ/2. Four metabolites having >25% of samples below LOQ were not further analyzed (C6, C5-OH:C3-DC, C4DC, and C10:2 acyl carnitines). All measurements were natural log-transformed prior to analysis, resulting in most metabolites approximating a normal distribution, an important consideration for variance components analysis. Eighteen metabolites did not meet this criterion, and therefore, linear regression models adjusted for body-mass index (BMI), age, sex, CAD, diabetes mellitus (DM (yes/no), hypertension (yes/no), and dyslipidemia (yes/no) were constructed for each of these metabolites, and the residuals were used for heritability estimates. Given occasional low trait standard deviations for metabolites (<0.5), all log transformed metabolites were multiplied by a factor of 4.7 prior to analysis.
Polygenic heritability models were then constructed. For the normally distributed metabolites (the majority of metabolites), polygenic heritability models were calculated using the log-transformed values, adjusting for age, sex, BMI, DM, dyslipidemia, hypertension and CAD. The proband and family members were not selected based on any metabolite values; however, the potential for ascertainment bias exists. Therefore, analyses were corrected based on which of the family members (proband) was the index member for ascertainment of the family for early-onset CAD. To account for factors such as diet (which are shared in households but are presumably not genetic) an additional variance component parameter corresponding to the fraction of variance associated with the effect of a common household (included in the model by a marker for residential address), was added to each model. All residual kurtoses for the final polygenic model were within normal range (i.e. <0.8), except for two amino acids (serine and phenylalanine), eleven acyl carnitines (C5, CIO, 00:1, 00:3, 02:1, 04, C14-OH:C12-DC, C16-OH:C14-DC, C18:1-0H, C18:1-DC, and 08-DC:C20-OH) and three free fatty acids (FAC 14:0, FAC 16:1, FAC 18:1). For these metabolites, removal of 1-4 of the most extreme values was necessary, which then resulted in a normal residual kurtosis. Two acylcarnitines required removal of a larger number of outliers to achieve a normal residual kurtosis (C16-OH:C14-DC and C12-OH:C10-DC), and hence, these results should be interpreted accordingly. For the eighteen non-normally distributed metabolites, standardized residuals from adjusted regression models were used to estimate heritabilities using SOLAR, but since the normalized deviates were already adjusted for relevant covariates heritability models using these residuals were not further adjusted. Estimates of the proportion of variance explained by clinical covariates are reported for these non-normally distributed metabolites as estimated using the adjusted polygenic model constructed from the log-transformed crude values.
For understanding quantitative differences in metabolites between families, multivariable generalized linear models adjusted for sex, age, BMI, CAD, DM, dyslipidemia and hypertension, were used to compare mean metabolite levels between families.
Unsupervised principal components analyses. Given that many metabolites reside in overlapping pathways, correlation of metabolites is expected. To understand the correlation, we used principal components analysis (PCA) to reduce the large number of correlated variables into clusters of fewer uncorrelated factors using raw metabolite values without removal of outliers. The factor with the highest “eigenvalue” accounts for the largest amount of the variability within the dataset. Standardized residuals calculated for each metabolite from linear regression models adjusted for age, sex, BMI, DM, and CAD, were used as input for PCA. PCA using residuals is recommended when, as in this case, the units for each variable vary significantly in magnitude (Johnson and Wichem D.W., 1988, Applied Multivariate Statistical Analysis. Prentice Hall, Englewood Cliffs, New Jersey.). Factors with an eigenvalue >1.0 were identified based on the commonly employed Kaiser criterion (Kaiser, 1960, Educational and Psychological Measurement, 20, 141-151). Varimax rotation was then performed to produce interpretable factors. Metabolites with a factor load >|0.4| are reported as composing a given factor, as is commonly used as an arbitrary threshold (Lawlor et al., 2004, Am JEpidemiol, 159, 1013-1018). Scoring coefficients were then used to compute factor scores for each individual (consisting of a weighted sum of the values of the standardized metabolites within that factor, weighted on the factor loading calculated for each individual metabolite). These factor scores were then used to calculate heritabilities for each factor with SOLAR as detailed above, using a polygenic model not further adjusted for covariables. Removal of 1-4 of the most extreme values for several of the factors was necessary to achieve a normal residual kurtosis.
As all analyses were exploratory in nature and given collinearity of the metabolites, nominal two-sided p-values unadjusted for multiple comparisons are presented, however results interpreted in the context of a conservative Bonferroni correction are reported. Nominal statistical significance was defined as p-value<0.05. Statistical analyses used SAS version 9.1 (SAS Institute, Cary NC), other than for heritability estimates which used SOLAR (Almasy et al., 1998, supra).
RESULTS AND DISCUSSION
Heritability Analysis. Metabolic profiling was performed on 117 individuals within eight multiplex Caucasian families (Figure 3) from the GENECARD study of premature CAD. Of note, the majority of family members sampled for this study were as-yet-unaffected offspring of the original affected-sibling-pair, but who, as members of these families, were at high risk for development of premature CAD. As expected, there was a high burden of CAD risk factors, although the prevalence differed between families (Table 13).
Table 13. Clinical characteristics of GENECARD families. The overall baseline clinical characteristics of the GENECARD cohort are presented, as well as baseline characteristics within each family.
HDL: high-density lipoprotein; LDL: low-density lipoprotein; BMI: body-mass-index
We found high heritabilities for conventional risk factors such as lipids and BMI (Figure 4). Total ketones (h2 0.75, p=3.8xl0'8) had the highest heritability among the metabolites analyzed by non-mass spectrometry-based methods, with similarly high heritability of the individual ketone β-hydroxybutyrate (h2 0.51, p=0.004). Among analytes measured by mass spectrometry, several amino acids had high heritability (Figure 5, Table 14). Arginine (ARG) had the highest score (h2 0.80, p=1.9xl0'16), with strong heritabilities also for glutamine/glutamate (GLX; h2 0.73, p=0.00006), alanine (ALA; h2 0.55, p=0.00002), proline (PRO; h2 0.52, p=0.00004), ornithine (ORN, h2 0.48, p=0.000005), phenylalanine (PHE; h2 0.46, p=0.0001), and the branched-chain amino acids leucine/isoleucine (LEU/ILE; h2 0.39, p=0.00005) and valine (VAL; h2 0.44, p=0.00006). Of the free fatty acids (Figure 5), FA-C20:4 (arachidonic acid, a key component in inflammatory pathways) was the most heritable (h2 0.59, p=0.00005), as well as FA-C18:2 (linoleic acid, precursor to arachidonic acid, h2 0.48, p=0.002). Many acylcarnitines also had high heritabilities (Figure 6, Table 14), the highest being the C18 acylcarnitines (C18, C18:l, and 08:2 , h2 0.39-0.82, p=0.0000007 -0.004); 04:1 (h2 0.79, p=0.0000002); C5:l (h2 0.67, p=0.000003); the CIOs (C10-OH:C8-DC, CIO and 00:1, h2 0.35-0.57, p=0.00003-0.02); 06 (h2 0.57, (p=0.0002); C4:Ci4 (h2 0.56, p=0.00003); short chain dicarboxylacylcarnitines (C5-DC, C6-DC, h2 0.45-0.51, p=0.003-0.004); and C2 acylcamitine (h2 0.50, p=0.00008). Interestingly, estimates for the genetic component of the variability of each metabolite often exceeded the proportion of variance explained by clinical covariates (Table 14).
Table 14. Heritabilities, clinical covariates and household effects for individual metabolites. Results for individual metabolites are presented, including: heritability point estimates, standard error for the heritability estimate, clinical covariates found to be significant in the polygenic model, the proportion of variance explained by household effects, the p-value for the household effects, the proportion of variance in the metabolite explained by those clinical covariates, and the p-value for the heritabilities.
*Clinical covariates (age, sex, BMI, hypertension, diabetes, dyslipidemia, CAD status) significant in polygenic model. •(Proportion of variance in metabolite levels accounted for by clinical covariates significant in the model. **P-value for heritability estimate. DM: diabetes mellitus; HTN: hypertension; BMI: body-mass-index; CAD: affected with premature CAD; DYS: dyslipidemia.
Metabolomic Profiles within Families. Given these strong findings, we sought to understand quantitative differences in metabolites between families. Multivariable linear models were used to test for differences in metabolites between families. Of the amino acids, glutamate, ornithine, arginine, proline, histidine, phenylalanine, alanine and methionine (all p<0.0001), leucine/isoleucine (p<0.0001) and valine (p=0.003) best differentiated families.
Of the acyl carnitines, the C18 (C18, 08:1, and 08:2) and the 04 acylcarnitines (04, 04:1) (all p<0.0001), along with C5:l (p<0.0001), and C2 (p<0.0001) acylcarnitines best differentiated families. Many free fatty acids differentiated families, the strongest being arachidonic and palmitic acid (both p<0.0001). Of the conventional metabolites, ketones (p<0.0001) and β-hydroxybutyrate (p=0.0001) best differentiated families.
Principal Components Analysis. Given correlation of metabolites in biological pathways, we performed PCA to understand which clusters of metabolites were correlated and to identify factors that were most heritable. Fifteen factors were identified, demonstrating biologically consistent relationships (Table 15). Factors accounting for the largest amount of variance within the dataset were Factor 1 (short- and medium-chain acylcamitines); Factor 2 (long-chain free fatty acids); Factor 3 (long-chain acylcamitines and amino acids [arginine, glutamate/glutamine, and ornithine] possibly reporting on mitochondrial function); Factor 4 (ketones, β-hydroxybutyrate, C2 and C4-OH [β-hydroxybutryl] acylcamitines; all markers of terminal steps of fatty acid oxidation); and Factor 5 (amino acids, including branched-chain amino acids, and C3 and C5 acylcamitines [by-products of branched-chain amino acid catabolism]). As expected, given results for individual metabolites, many factors were heritable.
Table 15. Principal components analysis in GENECARD. Results of PCA in the dataset are presented, including the key metabolites within each factor (i.e. those with a factor load >|0.4|); an overall biochemical description of the key metabolites within each factor; and the eigenvalue, total and cumulative variance, heritability and p-value for the heritability point estimate for each factor.
*Factor load >|0.4; FFA: free fatty acids; Tot Var: total variance; Cum Var: cumulative variance A comprehensive set of analytical tools was applied to gain a better understanding of the biochemical and physiologic underpinnings of cardiovascular disease, and how metabolomic profiles may relate to the known genetic component of CAD risk. Targeted, quantitative metabolic profiling was performed in multiplex families burdened with premature CAD, the majority representing offspring of the affected generation that had not yet developed CAD, but in whom we hypothesized similar metabolic profiles as their affected family members, if such profiles were heritable. High heritabilities were found for many metabolites, many with higher heritabilities than for conventional risk factors. These high heritabilities suggest a strong correlation between genotype and phenotype, implying a strong genetic component to clustering of these metabolic signatures in families burdened with CAD.
In addition, several individual metabolites distinguished families, the most prominent being, among the amino acids, arginine, ornithine, and glutamate/glutamine; and among the lipid-derived metabolites, the long-chain acyl carnitines C18:0, C18:1, and 08:2. These findings suggest fundamental differences in mitochondrial function in these families, consistent with prior studies showing relationships between impaired mitochondrial function and insulin resistance.
Given our studies were hypothesis-generating, we did not adjust for multiple comparisons. However, with a Bonferroni correction at the level of the factors, nine factors remain significant (p<0.003). We did not account for dietary pattern (known influence on metabolites), renal function, or medications (unknown influence). To help minimize these “non-genetic” effects, we incorporated a household effect and included married-in individuals, partially controlling for shared nutritional and other environmental effects. The measures of household effects suggest minimal influence on heritability estimates with high heritabilities despite adjustment. Therefore, we believe our results reflect both underlying genetic and environmental effects, similar to traditional cholesterol parameters. Accordingly, we found a significant household effect for LDL cholesterol (proportion of variance due to household 0.11, p=0.02), but with a significant heritability despite adjustment for this environmental effect (h2 0.37, p=0.004).
Similarly, results could reflect differences in essential versus non-essential metabolites. However, we found similar heritabilities for the essential (h2=0.40, p=0.0004) and non-essential (h2=0.63, p=0.00002) amino acids when analyzed as groups, and for the essential (h2=0.50, p=0.003) compared with the non-essential (h2=0.33, p=0.03) fatty acids. Although underpowered for such analyses, we also examined the relationship of age with heritabilities related to these groups. Age was a significant covariate on heritability estimates for both essential (valine) and nonessential (proline, ornithine, citrulline) amino acids (Table 14). For the free fatty acids, age was a covariate only for nonessential fatty acids (palmitoleic, oleic and stearic acid). We also examined correlations of metabolites with age and found that both essential (tyrosine, linoleic acid) and non-essential (glutamine, ornithine, citrulline, oleic acid) metabolites were significantly correlated with age (data not shown). Therefore, there does not seem to be a consistent variation of metabolites with age, nor with heritability estimates, based on essential/non-essential groups. This may indicate that fundamental and genetically controlled metabolic processes (e.g. mitochondrial or microsomal catabolic pathways) are influencing the levels of both essential and non-essential metabolites that utilize these common elements of the metabolic machinery.
Other factors that could impact heritability estimates include variability in sample collection or processing. We used a standardized protocol to limit this type of variability, intra-individual variation was low in a set of repeated assays, and family members were collected at different locations and times. A major strength of the study is the use of a very accurate, targeted, quantitative approach to metabolomic profiling, allowing us to dissect biological mechanisms underlying CAD pathophysiology. In addition to furthering the understanding of CAD pathophysiology, these results may have significant implications for risk prediction.
Each of the references cited herein is hereby incorporated by reference in its entirety.
It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.
In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word “comprise” or variations such as “comprises” or “comprising” is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
Claims (14)
1. A method for assessing risk of inherited cardiovascular disease in a subject comprising: (a) detecting in a sample from the subject the level of each metabolite in a group of metabolites consisting of C5-DC, C6-DC, C8:l-OH/C6:l-DC, and C8:1-DC; (b) calculating a weighted level of each metabolite by multiplying the detected level by a loading factor specific for each metabolite; (c) adding the weighted level of each metabolite in the group together to yield a factor score; (d) comparing the factor score of the sample to a non-cardiovascular disease standard; and (e) determining that the subject has an increased risk of inherited cardiovascular disease when the factor score in the subject is different from the standard.
2. The method of claim 1, wherein the cardiovascular disease is a cardiovascular event and the factor score in the subject being different from the standard is indicative of the risk of a cardiovascular event in the subject.
3. The method of claim 1, wherein the cardiovascular disease is coronary artery disease and the factor score in the subject being different from the standard is indicative of the presence of coronary artery disease in the subject.
4. The method of claim 1, wherein the cardiovascular disease is coronary artery disease and the factor score in the subject being different from the standard is indicative of the risk of developing coronary artery disease in the subject.
5. The method of any one of claims 1-4, wherein the sample is blood.
6. The method of any one of claims 1-5, wherein the level of each metabolite is detected using mass spectrometry.
7. A method for assessing risk of cardiovascular disease in a subject comprising: (a) detecting in a sample from the subject the level of each metabolite in a group of metabolites consisting of C5-DC, C6-DC, C8:l-OH/C6:l-DC, and C8:1-DC; (b) comparing the level of the at least one metabolite in the sample to a non-cardiovascular disease standard; and (c) determining that the subject has an increased risk of cardiovascular disease when the level of each metabolite is different from the standard.
8. A method for assessing the risk of inherited cardiovascular disease in a subject, comprising: obtaining a sample from the subject; providing the sample to a laboratory for detection of each metabolite in a group of metabolites consisting of C5-DC, C6-DC, C8:l-OH/C6:l-DC, and C8:1-DC; receiving from the laboratory a report indicating metabolite levels in the sample; and determining that the subject has an increased risk of inherited cardiovascular disease when the level of each metabolite is different from a non-cardiovascular disease standard.
9. The method of claim 7 or 8, wherein the cardiovascular disease is a cardiovascular event and the different level of each metabolite is indicative of the risk of a cardiovascular event in the subject.
10. The method of any one of claims 7-9, wherein the cardiovascular disease is coronary artery disease and the different level of each metabolite is indicative of the presence of coronary artery disease in the subject.
11. The method of any one of claims 7-9, wherein the cardiovascular disease is coronary artery disease and the different level of each metabolite is indicative of the risk of developing coronary artery disease in the subject.
12. The method of any one of claims 7-11, wherein the sample is blood.
13. The method of any one of claims 7-12, wherein the level of each metabolite is detected using mass spectrometry.
14. A method of developing a treatment plan for a subject comprising steps (a), (b), and (c) of claim 7, and further comprising (d) developing a treatment plan when an increased risk of inherited cardiovascular disease is determined in step (c).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015258285A AU2015258285B2 (en) | 2009-03-10 | 2015-11-20 | Predicting coronary artery disease and risk of cardiovascular events |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15907709P | 2009-03-10 | 2009-03-10 | |
US61/159,077 | 2009-03-10 | ||
PCT/US2010/026845 WO2010104964A1 (en) | 2009-03-10 | 2010-03-10 | Predicting coronary artery disease and risk of cardiovascular events |
AU2010224175A AU2010224175A1 (en) | 2009-03-10 | 2010-03-10 | Predicting coronary artery disease and risk of cardiovascular events |
AU2015258285A AU2015258285B2 (en) | 2009-03-10 | 2015-11-20 | Predicting coronary artery disease and risk of cardiovascular events |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2010224175A Division AU2010224175A1 (en) | 2009-03-10 | 2010-03-10 | Predicting coronary artery disease and risk of cardiovascular events |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2015258285A1 AU2015258285A1 (en) | 2015-12-10 |
AU2015258285B2 true AU2015258285B2 (en) | 2017-09-07 |
Family
ID=54774428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2015258285A Ceased AU2015258285B2 (en) | 2009-03-10 | 2015-11-20 | Predicting coronary artery disease and risk of cardiovascular events |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2015258285B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114487246B (en) * | 2022-01-07 | 2023-12-05 | 李继承 | Lipid metabolism marker composition for detecting acute myocardial infarction, kit and application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080073500A1 (en) * | 2006-03-02 | 2008-03-27 | Perkinelmer Las, Inc. | Distinguishing Isomers Using Mass Spectrometry |
-
2015
- 2015-11-20 AU AU2015258285A patent/AU2015258285B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080073500A1 (en) * | 2006-03-02 | 2008-03-27 | Perkinelmer Las, Inc. | Distinguishing Isomers Using Mass Spectrometry |
Also Published As
Publication number | Publication date |
---|---|
AU2015258285A1 (en) | 2015-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10317414B2 (en) | Predicting coronary artery disease and risk of cardiovascular events | |
Shah et al. | High heritability of metabolomic profiles in families burdened with premature cardiovascular disease | |
Batch et al. | Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness | |
Twerenbold et al. | High-sensitive troponin T measurements: what do we gain and what are the challenges? | |
EP2930512B1 (en) | Biomarkers for fatty liver disease and methods using the same | |
EP2164977A2 (en) | Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same | |
Park et al. | Urinary markers of fibrosis and risk of cardiovascular events and death in kidney transplant recipients: the FAVORIT trial | |
Wägner et al. | LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes | |
Sakanaka et al. | Saliva and plasma reflect metabolism altered by diabetes and periodontitis | |
Sheng et al. | Evaluation of the value of conventional and unconventional lipid parameters for predicting the risk of diabetes in a non-diabetic population | |
Barchetta et al. | Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus | |
AU2015258285B2 (en) | Predicting coronary artery disease and risk of cardiovascular events | |
Chou et al. | Lipoprotein (a) levels and risk of abdominal aortic aneurysm in the Women's Health Initiative | |
Šebeková et al. | Lean insulin-resistant young adults display increased cardiometabolic risk: A retrospective cross-sectional study | |
Jordanova et al. | New cut-off values of cardiac markers for risk stratification of angina pectoris | |
Tiong et al. | Asymmetric dimethylarginine and gestational diabetes mellitus: a systematic review and meta-analysis | |
Habieb et al. | Sirtuin1 and Sirtuin3 gene polymorphisms and acute myocardial infarction susceptibility | |
Siurana et al. | Different profiles of lipoprotein particles associate various degrees of cardiac involvement in adolescents with morbid obesity | |
Rinde et al. | Nitric oxide precursors and dimethylarginines as risk markers for accelerated measured GFR decline in the general population | |
WO2022175596A1 (en) | Use of glycoprotein acetyls for determining the risk of developing atrial fibrillation and/or flutter | |
WO2016149220A1 (en) | Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction | |
Alenbawi et al. | Genome-Wide Association Study and Meta-Analysis of Phytosterols Identifies a Novel Locus for Serum Levels of Campesterol | |
Kloska et al. | Reference values and biological determinants for cardiac myosin-binding protein C concentrations assessed with an enzyme-linked immunosorbent assay | |
EP4285123A1 (en) | Method for determining whether a subject is at risk of dying from breast cancer or prostate cancer | |
WO2024030680A1 (en) | Metabolic vulnerability analyzed by nmr |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |